PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar
The PPARA variant rs1800234 had a dose-dependent pharmacogenetic impact on the therapeutic response to chiglitazar. It could help explain the absence of a dose effect of chiglitazar and serve as a potential biomarker for the chosen dose of chiglitazar in the future. In addition, our study provided important reference for the design and clinical application of multi-target drugs.
Authors
- You Wang (ORCID: https://orcid.org/0000-0001-6992-2124)
- Yuanting Zheng (ORCID: https://orcid.org/0000-0003-4480-8303)
- Zhaoxu Geng (ORCID: https://orcid.org/0000-0001-6714-8382)
- Leming Shi (ORCID: https://orcid.org/0000-0002-2981-4150)
- Desi Pan (ORCID: https://orcid.org/0000-0002-2104-3902)
- Xianping Lu (ORCID: https://orcid.org/0000-0003-3933-0931)
- Qian Li (ORCID: https://orcid.org/0000-0003-0144-2372)
- Keying Li (ORCID: https://orcid.org/0000-0003-4431-9382)
- Ying Zhang (ORCID: https://orcid.org/0000-0001-7119-4760)
- Fei Chen
- Kaixin Zhou
Institutions
- Academy of Medical Sciences (GB)
- Chinese Academy of Sciences (CN)
- Fudan University (CN)
- China-Japan Friendship Hospital (CN)
- Shenzhen Metro (China) (CN)
- Guangzhou Experimental Station (CN)
- Shenzhen Bay Laboratory (CN)
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (CN)
- Institute of Biophysics (CN)
- Shandong First Medical University (CN)
- University of Chinese Academy of Sciences (CN)
- Shenzhen Chipscreen Biosciences Co.
- State Key Laboratory of Genetic Engineering
Publication Details
- Journal
- Pharmacogenomics
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1080/14622416.2024.2430163
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Sciences